Planned omalizumab discontinuation in CSU management as a sustainable strategy: A 2-year real-life study

Allergy. 2020 Oct;75(10):2681-2684. doi: 10.1111/all.14341. Epub 2020 May 25.

Affiliations

¹ Department of Emergency and Organ Transplantation, School and Chair of Allergology and Clinical Immunology, University of Bari - Aldo Moro, Bari, Italy.
² Department of Medical and Surgical Sciences, University of Foggia, Foggia, Italy.
³ Allergy and Clinical Immunology, Medicine and Surgery Department, University of Parma, Parma, Italy.

PMID: 32348578
DOI: 10.1111/all.14341

No abstract available

Publication types

Letter

MeSH terms

Anti-Allergic Agents* / therapeutic use
Chronic Disease
Humans
Omalizumab / therapeutic use
Treatment Outcome
Urticaria* / drug therapy

Substances

Anti-Allergic Agents
Omalizumab